Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Induction, Concurrent and Adjuvant Nivolumab Combined With Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 2, Multi-center, Single-arm Clinical Trial

Next Previous
Search
Trial Profile

Induction, Concurrent and Adjuvant Nivolumab Combined With Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 2, Multi-center, Single-arm Clinical Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Acronyms CANIRA

    • Most Recent Events

    • 04 Jun 2024 Results assessing nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin would obtain promising survival and low toxicity in high-risk LANPC were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 26 May 2024 Planned End Date changed from 30 Mar 2024 to 30 Mar 2026.
    • 03 Feb 2024 Planned End Date changed from 30 Dec 2026 to 30 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top